COVID-19 Vaccine Acceptance of Pregnant Women in Thailand
DOI: https://doi.org/10.2147/ijwh.s457740
2024-05-19
International Journal of Women s Health
Abstract:Bornpavi Nirunrungraung, Worashorn Lattiwongsakorn, &ast Wirawit Piyamongkol &ast Department of Obstetrics and Gynaecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand &astThese authors contributed equally to this work Correspondence: Worashorn Lattiwongsakorn; Wirawit Piyamongkol, Email ; Objective: This study investigated the COVID-19 vaccine acceptance rate among pregnant women in Thailand and explored factors influencing their willingness to receive the vaccine, to enhance vaccine uptake among hesitant pregnant women in the future. Methods: A prospective study was conducted at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, in October 2022. The data was collected using face-to-face questionnaires comprising 29 closed-end questions. Pregnant women aged 18 years old or over visiting the antenatal care clinic were included. Results: The study included 200 participants, revealing a COVID-19 vaccine acceptance rate of 17%. Healthcare provider recommendations significantly increased vaccine acceptance by nearly two-fold (30.77%, p-value < 0.01). The major cause of vaccine hesitancy was the concern about vaccine safety that potentially harmed their babies (77.44%). Conclusion: The COVID-19 vaccine acceptance rate among pregnant women in Thailand was low. Healthcare provider recommendations played a pivotal role in positively impacting vaccine acceptance, highlighting their importance in increasing acceptance rates in the future. Plain Language Summary: This study investigated the COVID-19 vaccine acceptance rate among pregnant women in Thailand and explored factors influencing their willingness to receive the vaccine. The study included 200 participants, revealing a COVID-19 vaccine acceptance rate of 17%. Healthcare provider recommendations significantly increased vaccine acceptance by nearly two-fold (30.77%, p-value < 0.01). The major cause of vaccine hesitancy was the concern about vaccine safety that potentially harming their babies (77.44%). The COVID-19 vaccine acceptance rate among pregnant women in Thailand was low. Healthcare provider recommendations played a pivotal role in positively impacting vaccine acceptance, highlighting their importance in increasing acceptance rates in the future. Keywords: COVID-19 disease, COVID-19 vaccine, pregnant women, vaccine acceptance, vaccine hesitancy In the current situation, there has been a rapid rise in the number of pregnant women infected with COVID-19 disease. This situation has brought to light the concerning escalation of morbidity and mortality rates among pregnant women compared to non-pregnant women. Specifically, pregnant women affected by COVID-19 are at a higher risk of adverse outcomes, including intensive care unit admissions, the necessity for invasive ventilation or extracorporeal membrane oxygenation, and even maternal mortality. Additionally, the implications of COVID-19 infection extend to pregnancy outcomes, notably leading to an increased incidence of preterm labor. Notably, infants born to infected mothers face a higher risk of neonatal intensive care unit admissions in comparison to those born to non-infected mothers. 1,2 While vaccination may not fully prevent breakthrough infections due to waning humoral immune responses 3–5 , vaccines have been found effective in mitigating disease severity, reducing hospitalization rates, and lowering mortality. Additionally, recent evidence highlights the effectiveness of vaccination in potentially lowering the risk of developing long COVID, 6 the most dreaded sequelae of acute infection, which can persist for up to two years. 7 COVID-19 vaccination is an important strategy to mitigate the risks of complications for both mothers and fetuses. Recognizing its significance, the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal-Fetal Medicine (SMFM), and the Centers for Disease Control and Prevention (CDC) strongly recommend COVID-19 vaccination during pregnancy. 8–10 Their collective consensus rests on the pillars of safety and efficacy. 11 For individuals who have not received vaccination before pregnancy, the recommended approach involves initiating a two-dose mRNA vaccine series at any point during pregnancy, followed by a bivalent booster administered two months after the last dose of the primary series. Similarly, those who completed their primary vaccination series before pregnancy are advised to undergo bivalent boosters, administered two months after the last dose of the primary series. 12 Drawing insights from international studies on COVID-19 acceptance during pregnancy, American pregnant women exhibite -Abstract Truncated-
obstetrics & gynecology